Data presented at the European Society of Cardiology meeting demonstrated that Novartis' cholesterol-lowering medication Leqvio rapidly improved lipid profiles in high-risk patients when added to standard care. The Phase 4 findings confirm the drug’s efficacy in managing hyperlipidemia and suggest potential ancillary benefits, including reductions in muscle pain commonly associated with statin therapies. These outcomes support Leqvio's role in cardiovascular risk management and could influence clinical guidelines.